Converge Bio has raised $5.5 million in seed funding led by TLV Partners.WHAT IT DOES
Converge Bio is a generative AI hub for Biotech and Pharma that allows the accelerated discovery and development of drugs…
Margaret Anderson, Managing Director at Deloitte Consulting LLP
In response to the COVID-19 pandemic, the biomedical community took on the task of developing and deploying critical interventions to address an unprecedented public health emergency. In…
Continue Reading
Researchers at MIT have developed a printer that can create large numbers of microneedle patch-style vaccines in places where they are needed quickly. Moreover, the printed patches can deliver thermostable mRNA vaccines, whereby the…
Continue Reading
What You Should Know:– A nationwide U.S. study of more than 893,000 adults provides solid evidence confirming that mRNA booster immunizations extend protection against moderate and severe COVID for four to five months. – These…
Continue Reading
Top News
The VA postpones its planned July 2023 Oracle Cerner go-live at its Ann Arbor, MI facilities until later this year or early in 2024.
The service region is concerned about “how well EHRM would interact with VA Ann Arbor’s vital medical research mission.”
Reader Comments From AT: “Re: pet peeves with service industry words and phrases. ‘I appreciate you,’ following my thanking you and leaving you a tip, which suggests that we are like-minded, decent people even though you have no way of knowing that. Second is thanking someone with ‘of course,” implying that I’m either too stupid to know…
Continue Reading
A Moderna messenger RNA vaccine for influenza now has preliminary data from a pivotal study showing the shot prompted a strong immune response to the more common strains of the virus but fell short against less common strains.
The results reported Thursday are from one of two pivotal studies for the Moderna vaccine, mRNA-1010, which is assessing the shot for safety and immune response. A separate Phase 3 study is evaluating the shot for efficacy. Results from that study could come as early as next month. Moderna’s vaccine encodes hemagglutinin, a protein on the surface of the influenza virus that is also…
Vir Biotechnology’s Covid-19 research may yield more drugs and perhaps a vaccine, but no longer with the financial support of GSK. The collaboration agreement the two companies struck up in the early days of the pandemic has been amended, leaving Vir to either find another partner or continue its coronavirus research on its own.
The alliance did successfully develop the Covid-19 drug sotrovimab. GSK and Vir will continue to share responsibilities for that drug, which is available under the brand name Xevudy in more than 40 countries. The U.S. is no longer one of them. Last April, the FDA withdrew emergency authorization…
